SLV-308. Solvay.
Article Details
- CitationCopy to clipboard
Wolf WA
SLV-308. Solvay.
Curr Opin Investig Drugs. 2003 Jul;4(7):878-82.
- PubMed ID
- 14619412 [ View in PubMed]
- Abstract
Solvay is developing SLV-308 (SME-308), a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties, for the potential oral treatment of Parkinson's disease (PD), panic and depression. By January 2001, SLV-308 had entered phase II trials for PD and phase I trials for anxiety and depression.
DrugBank Data that Cites this Article
- Drugs